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Sirtuin deacetylases are linked to longevity, aging, and stress responses. In this issue of Cancer Cell, Kim
et al. show that SIRT3 functions as a tumor suppressor by enhancing the expression of mitochondrial
MnSOD. Loss of SIRT3 leads to increased mitochondrial ROS, which then enhances cellular transformation
and tumor growth.The sirtuins family of histone deacety-
lases affect diverse biological processes,
including longevity, aging, and the re-
sponse to stress. Humans express seven
sirtuins (SIRT1-7), whose functions have
become the focus of intense investiga-
tion. Three mammalian sirtuins are tar-
geted to mitochondria (SIRT3, 4, and 5),
whereas the remainder exhibit cytosolic
and/or nuclear localization. Initial excite-
ment regarding sirtuins arose with the
realization that they mediate the increase
in lifespan arising from caloric restriction
(Guarente, 2008), although the underlying
mechanism is unknown. SIRT3 is the only
member linked genetically to lifespan in
humans (Rose et al., 2003), which,
together with its localization in mitochon-
dria, has made SIRT3 an especially inter-
esting target for study.
Surprisingly, deletion of Sirt3 in the
mouseproducesnoovert signsofdisorder
(Lombard et al., 2007). However, a
different picture emerges when these
animals are stressed. For example, cardi-
omyocytes from Sirt3-deficient mice
exhibit increased levels of reactive oxygen
species (ROS), decreased ATP levels, and
intolerance to oxidant stress (Sundaresan
et al., 2008). Wild-type mice challenged
with angiotensin II (to increase cardiac
workload) develop myocardial hyper-
trophy, whereas Sirt3/ mice exhibit
a massively amplified response (Sundare-
san et al., 2009). In wild-type animals,
treatmentwithNAD, an activator of SIRT3,
blocked the hypertrophic response by
suppressing Akt activation via an LKB1-
AMPK-mediated pathway (Pillai et al.,
2009). Thus, SIRT3 is important in regu-
lating the response to stress.
Given that SIRT3 localizes to mitochon-
dria, that mitochondrial ROS are impor-
tant in cancer, and that SIRT3 expressiondecreases with aging (Lanza et al., 2008),
one might ask whether SIRT3 plays a role
in oncogenic transformation. The answer,
detailed in an impressive set of studies in
this issue (Kimet al., 2010), is a resounding
yes. The authors began by comparing
ROS in wild-type and Sirt3/ murine
embryonic fibroblasts (MEFs). Under
basal conditions, there were no differ-
ences in cytosolic ROS. However, when
stressed by treatments that augment
ROS generation, the increases in ROS
they observed were greater in the Sirt3/
cells. Even greater differences were
seen when they used a probe to detect
mitochondrial oxidant stress, during
which they detected higher ROS levels
even under unstressed conditions. These
higher ROS levels correlated with a pro-
gressive deterioration in liver mitochon-
drial DNA integrity, over 58 weeks of age.
Although oxidant stress and genomic
instability might promote transformation,
the SIRT3-deficient MEFs were not
immortalized. Thus, loss of Sirt3 pushes
the cell toward a transformed phenotype,
but not enough to induce transformation.
However, when the stress of expressing
Myc and/or Ras was added to Sirt3/
MEFs, the cells became immortalized,
they lost contact inhibition and they grew
more quickly. By contrast, wild-type cells
required both Myc and Ras to achieve a
similar phenotype. Moreover, Sirt3/
MEFs expressing Myc or Ras grew in soft
agar and developed subcutaneous tumors
in nude mice. In wild-type MEFs, expres-
sion of Myc or Ras alone is insufficient to
permit soft-agar or in vivo tumor growth.
Thus, SIRT3 functions as a tumor suppres-
sor, and loss of SIRT3 amplifies the pheno-
typic effects of oncogene expression.
How does loss of SIRT3 alter mitochon-
drial ROS? On the basis of its mitochon-Cancer Celldrial localization, and the finding that
ROS levels were increased in Sirt3/
cells, Kim et al. (2010) examined the mito-
chondria. They found that glycolytic
activity was increased, whereas mito-
chondrial ATP levels and maximal ca-
pacity of complexes I and III were reduced
in the Sirt3/ Myc/Ras cells. ROS-medi-
ated damage to mitochondrial DNA might
explain these changes, although loss of
mitochondrial protein deacetylation in
the Sirt3/ cells might also contribute
(Figure 1). In either case, the increase in
mitochondrial ROS was an important
clue. In mitochondria, a principal antioxi-
dant component is MnSOD, which
degrades superoxide into H2O2. Sure
enough, they found that MnSOD protein
levels were decreased in the Sirt3/
Myc/Ras fibroblasts. Moreover, en-
hanced expression of MnSOD in Sirt3/
Myc/Ras cells slowed their growth, and
coexpression of MnSOD prevented the
immortalization of Sirt3/ cells express-
ing either Myc or Ras. Thus, increased
mitochondrial superoxide appears to
mediate the transformation of Sirt3
knockout cells expressing an oncogene.
Why does loss of SIRT3 decrease the
expression of MnSOD? SIRT3 activates
the expression of MnSOD and catalase
by promoting FOXO3a translocation to
the nucleus (Sundaresan et al., 2009).
Loss of SIRT3 leads to increased FOXO3a
phosphorylation, triggering its nuclear
export. Thus, the nuclear/cytosolic func-
tions of SIRT3, rather than the mitochon-
drial, mediate its role in the regulation of
this key antioxidant (Figure 1). Indeed,
expression of wild-type SIRT3 in Sirt3/
cells normalized mitochondrial ROS and
MnSOD expression, whereas mutant
SIRT3 lacking deacetylase activity failed
to do so (Kim et al., 2010). Hence, SIRT317, January 19, 2010 ª2010 Elsevier Inc. 5
Figure 1. SIRT3 Regulates the Expression of MnSOD
SIRT3, a mitochondria-targeted deacetylase, plays an important role in regulating cell transformation,
intriguingly, by its indirect effects in the cytosol, where it controls FOXO3a nuclear trafficking and thereby
affects MnSOD expression. The MnSOD is a critical regulator of mitochondrial superoxide levels, which
appear to regulate cellular transformation. Thus, loss of SIRT3 pushes the cell toward a transformed
phenotype by enhancingmitochondrial ROS,which can also induce genetic instability and the stabilization
of hypoxia-inducible factor (HIF).
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lating mitochondrial ROS via the regula-
tion of FOXO3a.
How does the loss of MnSOD promote
tumor formation? Kim et al. (2010) found
that MnSOD expression declined in the
Sirt3/ mice as they aged. Although the
underlying mechanism is unclear, they
observed a higher incidence of sponta-
neous mammary gland tumors in the
knockouts compared with wild-type
mice, along with evidence of higher
oxidant stress. Does loss of MnSOD
promote tumor formation by itself? Inter-
estingly, mice heterozygous for MnSOD
initially appeared to be normal, but later
also show an enhanced incidence of
mammary tumors (Van Remmen et al.,
1999). Thus, partial loss ofMnSODpushes
cells toward oncogenic transformation by
decreasing the number of other mutations
needed to grow tumors. This is precisely
the definition of a tumor suppressor.
Kim et al. (2010) reveal novel aspects of
SIRT3 in regulating transformation while
confirming other studies linking SIRT3
to the regulation of mitochondrial ROS
(Sundaresan et al., 2009). However, other
issues remain. First, although SIRT3 may
localize to mitochondria, its effects on
mitochondria are mediated by its regula-6 Cancer Cell 17, January 19, 2010 ª2010 Eltion of FOXO3a in the cytosol/nucleus. If
the principal effects of SIRT3 are unre-
lated to its localization in mitochondria,
what is it doing there? This question could
be addressed by targeting the expression
of SIRT3 to various mitochondrial com-
partments in Sirt3/ Myc/Ras cells and
examining the consequences for the
transformation phenotype.
Another issue concerns the relationship
between mitochondrial superoxide and
transformation. Kim et al. (2010) show
decreased MnSOD levels and increased
mitochondrial superoxide in the Sirt3/
cells, which drive proliferation and trans-
formation behavior. Yet ROS levels in
the cytosol, intermembrane space, and
matrix compartment are regulated inde-
pendently (Waypa et al., 2009), and it is
difficult for superoxide to travel from the
matrix to the cytosol because anion chan-
nels are needed to traverse membranes.
Under basal conditions, the Sirt3/ cells
showed no increase in cytosolic oxidant
stress. So how does superoxide trapped
in the mitochondrial matrix push the cells
in the direction of transformation? Could
the SIRT3molecules localized to themito-
chondria be playing a complementary role
by regulating the release of ROS to the
cytosol? Studies using the targetedsevier Inc.rescue constructs described above could
help to address this question.
Kim et al. (2010) reinforce an important
concept in cancer biology—that mito-
chondrial ROS play an important role in
promoting transformation and tumor
progression. It seems likely that ROS-
mediated inactivation of protein and lipid
phosphatases, whose active sites contain
redox-sensitive cysteine thiols, may be
responsible. Therapeutically, is there a
way to exploit SIRT3 to minimize undesir-
able ROS signaling? One idea is to supply
NAD to cells to enhance SIRT3 activity.
Recently, Pillai et al. show that NAD
administered to wild-type, but not
Sirt3/ mice, abolished the cardiac
hypertrophic response to angiotensin II
(Pillai et al., 2009). In tumors in which
loss of SIRT3 may contribute to the trans-
formed phenotype, it is worth considering
whether NAD administration could drive
the cells in a reverse direction along the
transformation pathway.
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